Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 99 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Novolin R Clear all
Completed Phase 4 Interventional Results available

Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes

NCT01774968
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Human Regular U-500 Insulin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
35
States / cities
Mobile, Alabama • Little Rock, Arkansas • Concord, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2015 · Synced Sep 2, 2026, 5:38 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Insulin Modulation of fMRI Connectivity in Healthy Adults

NCT02982551
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Insulin, Taste Task, Magnetic Resonance Imaging, Dextrose
Drug · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years to 30 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2017 · Synced Sep 2, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders

NCT03943537
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizo Affective Disorder, Bipolar I Disorder
Interventions
Intranasal Insulin
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2025 · Synced Sep 2, 2026, 5:38 PM EDT
Completed Phase 1 Interventional

Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Type 1 Diabetics

NCT00752180
View directory record Official record
Conditions
Diabetes
Interventions
Wosulin R, Actrapid
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2012 · Synced Sep 2, 2026, 5:38 PM EDT
Withdrawn Phase 1 Interventional

Dexamethasone/Pancreatic Clamp P&F

NCT06126354
View directory record Official record
Conditions
Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease, Overweight and Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Human Growth Hormone, Dexamethasone Oral, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer, Normal saline, Human albumin
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 2, 2026, 5:38 PM EDT
Completed Not applicable Interventional

The Effect of Intensive Insulin Therapy in the Surgical Critical Care Unit

NCT00282594
View directory record Official record
Conditions
Sepsis, Respiratory Failure, Renal Failure, Surgical Site Infection
Interventions
Novolin R (human recombinant Insulin)
Drug
Lead sponsor
Genesys
Other
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Grand Blanc, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 26, 2006 · Synced Sep 2, 2026, 5:38 PM EDT
Terminated Phase 2Phase 3 Interventional

Effects of Pulsatile Intravenous Insulin Therapy on Metabolic Integrity in Patients With Diabetes Mellitus

NCT00539409
View directory record Official record
Conditions
Diabetes Mellitus, With Complications
Interventions
Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
21 Years to 85 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Sep 2, 2026, 5:38 PM EDT
Completed Not applicable Interventional Results available

Regular Insulin vs Rapid Insulin Delivered by V-Go

NCT03495908
View directory record Official record
Conditions
Type 2 Diabetes, Type 2 Diabetes Mellitus
Interventions
VGo
Device
Lead sponsor
East Coast Institute for Research
Network
Eligibility
21 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Jacksonville, Florida • Macon, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Sep 2, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Intranasal Insulin in Parkinson's Disease

NCT04251585
View directory record Official record
Conditions
Parkinson Disease
Interventions
Regular Novolin R, Placebo
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
41 Years to 89 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 2, 2026, 5:38 PM EDT
Terminated Not applicable Interventional Results available

The Association Between Peri-Operative Hyperglycemia and Major Morbidity and Mortality

NCT00487162
View directory record Official record
Conditions
Hyperglycemia
Interventions
intensive glycemic control, conventional glycemic control
Procedure · Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 95 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Sep 2, 2026, 5:38 PM EDT
Completed Phase 4 Interventional Results available

Veterans Inpatient Insulin Study and Transition to Outpatient Therapy

NCT00821795
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
NPH/Regular 70/30 mix, insulin aspart protamine/insulin aspart 70/30 mix
Drug
Lead sponsor
Dennis G. Karounos, M.D.
Federal
Eligibility
40 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Sep 2, 2026, 5:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Intake and Intra-Nasal Insulin for African American Adults (FIINAAL)

NCT04739371
View directory record Official record
Conditions
Insulin
Interventions
Insulin, Regular, Human, Placebo
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
45 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 2, 2026, 5:38 PM EDT
Completed Phase 4 Interventional Results available

Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (T2DM)

NCT00979628
View directory record Official record
Conditions
Type 2 Diabetes, Hyperglycemia
Interventions
sliding scale regular insulin (SSRI), Basal Bolus, Basal Plus
Drug
Lead sponsor
Guillermo Umpierrez, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Atlanta, Georgia • Decatur, Georgia • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Sep 2, 2026, 5:38 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Neural Mechanism of Aldosterone-induced Insulin Resistance

NCT02102243
View directory record Official record
Conditions
Hypertension
Interventions
DEFINITY® infusion, Human Recombinant Regular Insulin infusion, Dextrose infusion, Flow mediated vasodilation, Endothelial cell collection, Microvascular perfusion assessment using Definity, Microneurography
Drug · Procedure
Lead sponsor
Wanpen Vongpatanasin
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Sep 2, 2026, 5:38 PM EDT
Completed Not applicable Interventional Results available

Recombinant Human Leptin Therapy Effects on Insulin Action

NCT01207934
View directory record Official record
Conditions
Type Two Diabetes Mellitus
Interventions
placebo, low-dose leptin, high-dose leptin
Dietary Supplement · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
25 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Sep 2, 2026, 5:38 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Neuro Biomarkers of Smoking Behavior

NCT03811951
View directory record Official record
Conditions
Smoking Cessation
Interventions
Novolin R
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
21 Years to 40 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Sep 2, 2026, 5:38 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Comparison Study of Insulin Glargine and NPH Insulin

NCT01854723
View directory record Official record
Conditions
Diabetes
Interventions
Switching to NPH insulin, Continuation of insulin glargine
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
Up to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Sep 2, 2026, 5:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Wockhardt's Glucose Clamp Study-Human Isophane Susp 30IU/ml/70IU/ml With Novolin70/30, in Healthy Subjects

NCT01358435
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
30% Regular Insulin Human Neutral and 70%Isophane Insulin, Novolin 70/30
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 45 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2012 · Synced Sep 2, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Enhancement of Cerebral Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes

NCT01206322
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Intranasal insulin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Sep 2, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin.

NCT02064166
View directory record Official record
Conditions
Parkinson Disease, Multiple System Atrophy
Interventions
Intranasal Insulin
Drug
Lead sponsor
Peter Novak
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 22, 2018 · Synced Sep 2, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

SNIFF - Combo INI+EMPA Trial

NCT05081219
View directory record Official record
Conditions
Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease
Interventions
Insulin (Humulin® R U-100), Empagliflozin 10 MG, Aptar Pharma CPS Intranasal Delivery Device, Placebo (Insulin Diluent), Placebo (Capsules)
Drug · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years to 85 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 2, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Memory Aid by Intranasal Insulin in Diabetes (MemAID)

NCT02415556
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Regular Human Insulin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years to 85 Years
Enrollment
289 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Sep 2, 2026, 5:38 PM EDT
Completed Phase 2Phase 3 Interventional Results available

The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)

NCT01767909
View directory record Official record
Conditions
Amnestic Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Insulin (Humulin® R U-100), Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 85 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Irvine, California • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 2, 2026, 5:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Novolin R, in Healthy Subjects.

NCT00596063
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Wosulin R, Novolin R
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
2
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2012 · Synced Sep 2, 2026, 5:38 PM EDT